share_log

Citigroup Initiates Coverage On Prime Medicine With Neutral Rating, Announces Price Target of $10

Citigroup Initiates Coverage On Prime Medicine With Neutral Rating, Announces Price Target of $10

花旗集团以中性评级启动优质药品保险,宣布目标股价为10美元
Benzinga ·  2023/12/08 07:38

Citigroup analyst Samantha Semenkow initiates coverage on Prime Medicine (NASDAQ:PRME) with a Neutral rating and announces Price Target of $10.

花旗集团分析师萨曼莎·塞门科以中性评级启动了对Prime Medicine(纳斯达克股票代码:PRME)的报道,并宣布目标股价为10美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发